Daron Evans Buys 40,000 Shares of Rezolute (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 40,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were bought at an average cost of $1.77 per share, for a total transaction of $70,800.00. Following the transaction, the chief financial officer owned 415,900 shares in the company, valued at $736,143. The trade was a 10.64% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Daron Evans also recently made the following trade(s):

• On Monday, December 15th, Daron Evans purchased 5,000 shares of Rezolute stock. The stock was bought at an average cost of $1.79 per share, with a total value of $8,950.00.

Rezolute Trading Down 9.4%

Shares of NASDAQ RZLT traded down $0.17 during midday trading on Monday, reaching $1.63. The company had a trading volume of 13,380,965 shares, compared to its average volume of 9,712,468. Rezolute, Inc. has a 1 year low of $1.07 and a 1 year high of $11.46. The business’s 50-day simple moving average is $9.00 and its 200 day simple moving average is $7.17. The stock has a market cap of $151.15 million, a P/E ratio of -1.75 and a beta of 0.21.

Rezolute (NASDAQ:RZLT) last released its earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. Analysts predict that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RZLT has been the topic of several recent research reports. Cantor Fitzgerald downgraded shares of Rezolute from an “overweight” rating to a “neutral” rating in a report on Thursday. Craig Hallum lowered Rezolute from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Thursday. Guggenheim decreased their price objective on Rezolute from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Friday. JMP Securities set a $17.00 price objective on shares of Rezolute in a research note on Wednesday, October 29th. Finally, BTIG Research reissued a “buy” rating and issued a $5.00 target price on shares of Rezolute in a research note on Thursday. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.78.

Institutional Trading of Rezolute

A number of institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. boosted its stake in shares of Rezolute by 5.2% in the first quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock valued at $197,000 after purchasing an additional 3,334 shares during the period. Pale Fire Capital SE boosted its position in Rezolute by 9.1% in the 1st quarter. Pale Fire Capital SE now owns 47,122 shares of the company’s stock valued at $137,000 after buying an additional 3,935 shares during the period. Affinity Asset Advisors LLC grew its stake in shares of Rezolute by 7.9% in the first quarter. Affinity Asset Advisors LLC now owns 1,700,000 shares of the company’s stock worth $4,930,000 after acquiring an additional 125,000 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in shares of Rezolute by 56.4% in the first quarter. OMERS ADMINISTRATION Corp now owns 118,900 shares of the company’s stock worth $345,000 after acquiring an additional 42,900 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in shares of Rezolute by 335.4% during the first quarter. Cubist Systematic Strategies LLC now owns 210,581 shares of the company’s stock worth $611,000 after acquiring an additional 162,216 shares during the period. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.